LEO Pharma thrombosis business unit executive vice-president Jean Monin stated: “We are excited to partner with Junshi Biosciences, supplementing LEO Pharma’s Thrombosis busin ...
Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...
2d
Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing ...
General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...
01877 JUNSHI BIO Announcements and Notices - (Profit Warning / Inside Information) 01877 JUNSHI BIO Announcements and Notices - (Overseas Regulatory Announcement - Oth 01919 COSCO SHIP HOLD Next Day ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback